Bumrungrad Hospital Public Company (BUHPF) Fair Value & Analysis
Healthcare · US · Market cap $4.4B
Bumrungrad Hospital Public Company
BUHPF · US
Fair value as of: Jul 15, 2026
From 26 valuation models · updated 26 days ago
Fair value updated Jul 15, 2026, revised from $5.07 to $4.68 (−7.7%) since Jun 24, 2026.
A solid business, but screening 14% overvalued on our models.
What matters now
- A fairly wide model range ($3.13 to $6.25) leaves room in how you read the outcome.
- Our model range runs from $3.13 (bear) to $6.25 (bull), base $4.68. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year. As of Jul 15, 2026.
How to read this chart
60‑month range $2.62 – $8.17 · fair‑value band $3.13 – $6.25 · the $5.45 price screens above the $4.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Jul 15, 2026.
Analysis
Bumrungrad Hospital Public Company (BUHPF) currently trades at $5.45, while our model-based Fair Value estimate is $4.68, implying the stock looks roughly 14.1% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Bumrungrad Hospital Public Company generated revenue of $25.5B at a net margin of 29.7%. Revenue grew 0.7% year over year. It earns a return on equity of 24.4%. The balance sheet holds a net cash position of $7.1B. Fundamentals as of Jul 15, 2026
Our scenario range runs from $3.13 (bear case) to $6.25 (bull case); at $5.45, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 7% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -14%, BUHPF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings ($5.22) versus Asset-Based ($0.7656). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally.
Full company description
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers. In addition, it operates spine institute, heart institute, and intensive care unit; and offers nutrition services, pharmacy services, preventive genomics and integrative medicine services. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bumrungrad Hospital Public Company reported revenue of $25.1B in FY2025 versus $12.5B in FY2021, a compound +19.2%/yr. Reported net income was $7.5B in FY2025, compounding +57.6%/yr from FY2021.
BUHPF screens 14% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Bumrungrad Hospital Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bumrungrad Hospital Public Company (BUHPF) overvalued or undervalued?
What is the fair value of BUHPF?
What is the quality score of BUHPF?
What is the revenue of Bumrungrad Hospital Public Company (BUHPF)?
What is the net profit margin of BUHPF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bumrungrad Hospital Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.